Investors

Share price and stock information, benchmark, orders, transactions: find out Ipsen share-related data.

• Listed on: segment A of Euronext Paris
• ISIN code: FR 0010259150
• Mnemonic: IPN
• FTSE classification: 486 – pharmaceuticals
• Sectorial classification ICB: 4577 – pharmaceuticals
• Nominal value: 1 euro
• First trading day: December 7, 2005

Our top-line sales growth and bottom-line performance in 2018 were better than they have ever been – and our pipeline is stronger than ever.

2019 Financial guidance

 The Group has set the following financial targets for 2019:

• Group sales growth year-on-year at constant currency greater than +13.0%; based on the current level of exchange rates, sales growth at current rates would be positively impacted by around 1.0%.
• Core operating margin around 31.0% of net sales, excluding incremental investments in pipeline expansion initiatives.

On May 11, 2017, the Group updated financial guidance for 2020 to reflect the contribution of the acquisitions announced in early 2017, the change of definition of Core Operating Income (to exclude the amortization of intangible assets and the gain or loss on disposal of fixed assets) and the strong performance of the Specialty Care business over the last 15 months.

• Sales in excess of 2.5 billion euros;
• Core operating margin greater than 30% .

This guidance includes the contribution from the recent 2017 acquisitions and excludes the impact from any further business development (other than development costs associated with potential new early to mid-stage R&D assets). It also covers the impact from potential Somatuline® competitive threats.